Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Cancer Res. 2017 Apr 26;77(13):3666–3671. doi: 10.1158/0008-5472.CAN-16-3338

Figure 2.

Figure 2

(A) Venn diagram for all 13,349 samples from discovery and replication set combined showing proportion that could respond to targeted, checkpoint inhibitor and combination therapy in our analysis. (B) Stacked plot shows the percent of patients suitable for combination therapy that presents each studied gene mutation in samples. Patients can be in more than one category since patients can have multiple genes mutated. (C) Stacked plot shows, for each studied gene, the proportion of mutated patients that presents criteria for combination therapy. Patients can be in more than one category since patients can have multiple genes mutated.